文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

美国脓毒症肾脏替代治疗的医院间差异

Hospital Variation in Renal Replacement Therapy for Sepsis in the United States.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论美国440家医院脓毒症合并急性肾损伤患者急性肾脏替代治疗使用率中位数3.6%,医院间差异大但与住院死亡率无关,使用率越高住院费用越高。

该回顾性队列研究基于2011年全国住院患者样本,纳入18岁及以上脓毒症合并急性肾损伤住院患者293,899例,分布于440家医院,其中6.4%(n=18,885)接受了肾脏替代治疗。经风险和可靠性调整后,医院肾脏替代治疗率中位数为3.6%(四分位距2.9%-4.5%),最高五分位医院为4.8%-13.4%。医院特异性肾脏替代治疗率与住院死亡率无显著关联(肾脏替代治疗率每增加1%的比值比1.03;95%CI 0.99-1.07;p=0.10),但住院费用随肾脏替代治疗率升高而显著增加(每增加1%绝对费用增加1,316美元;95%CI 157-2,475美元;p=0.03)。作者认为改善脓毒症肾脏替代治疗启动标准可能降低医疗费用而不增加死亡率。

要点

  • 2011年美国440家医院293,899例脓毒症合并急性肾损伤住院患者中,6.4%(n=18,885)接受了肾脏替代治疗。
  • 风险与可靠性调整后,医院肾脏替代治疗率中位数3.6%(四分位距2.9%-4.5%),最高五分位医院达4.8%-13.4%,院间差异大。
  • 医院肾脏替代治疗率与住院死亡率无显著关联(每增加1%的比值比1.03;95%CI 0.99-1.07;p=0.10)。
  • 住院费用随肾脏替代治疗率升高而显著增加(每增加1%绝对费用增加1,316美元;95%CI 157-2,475美元;p=0.03)。
  • 作者认为改善脓毒症肾脏替代治疗启动标准可能降低医疗费用而不增加死亡率。

适用人群与场景

  • 18岁及以上脓毒症合并急性肾损伤患者,来自2011年全国住院患者样本抽样的440家医院。

研究设计与关键结果

  • 回顾性队列研究,基于2011年全国住院患者样本,纳入293,899例脓毒症合并急性肾损伤住院患者,分布于440家医院,其中6.4%(n=18,885)接受肾脏替代治疗。
  • 经风险和可靠性调整后,医院肾脏替代治疗率中位数为3.6%(四分位距2.9%-4.5%),最高五分位医院为4.8%-13.4%。
  • 医院特异性肾脏替代治疗率与住院死亡率无显著关联(肾脏替代治疗率每增加1%的比值比1.03;95%CI 0.99-1.07;p=0.10)。
  • 住院费用随肾脏替代治疗率升高而显著增加(肾脏替代治疗率每增加1%绝对费用增加1,316美元;95%CI 157-2,475美元;p=0.03)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究显示医院间脓毒症肾脏替代治疗使用率差异大且与死亡率无关,提示启动标准不统一可能影响费用;作者认为改善脓毒症肾脏替代治疗启动标准可能降低医疗费用而不增加死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Acute renal replacement therapy in patients with sepsis has increased dramatically with substantial costs. However, the extent of variability in use across hospitals-and whether greater use is associated with better outcomes-is unknown.

DESIGN: Retrospective cohort study.

SETTING: Nationwide Inpatient Sample in 2011.

PATIENTS: Eighteen years old and older with sepsis and acute kidney injury admitted to hospitals sampled by the Nationwide Inpatient Sample in 2011.

INTERVENTIONS: We estimated the risk- and reliability-adjusted rate of acute renal replacement therapy use for patients with sepsis and acute kidney injury at each hospital. We examined the association between hospital-specific renal replacement therapy rate and in-hospital mortality and hospital costs after adjusting for patient and hospital characteristics.

MEASUREMENTS AND MAIN RESULTS: We identified 293,899 hospitalizations with sepsis and acute kidney injury at 440 hospitals, of which 6.4% (n = 18,885) received renal replacement therapy. After risk and reliability adjustment, the median hospital renal replacement therapy rate for patients with sepsis and acute kidney injury was 3.6% (interquartile range, 2.9-4.5%). However, hospitals in the top quintile of renal replacement therapy use had rates ranging from 4.8% to 13.4%. There was no significant association between hospital-specific renal replacement therapy rate and in-hospital mortality (odds ratio per 1% increase in renal replacement therapy rate: 1.03; 95% CI, 0.99-1.07; p = 0.10). Hospital costs were significantly higher with increasing renal replacement therapy rates (absolute cost increase per 1% increase in renal replacement therapy rate: $1,316; 95% CI, $157-$2,475; p = 0.03).

CONCLUSIONS: Use of renal replacement therapy in sepsis varied widely among nationally sampled hospitals without associated differences in mortality. Improving renal replacement standards for the initiation of therapy for sepsis may reduce healthcare costs without increasing mortality.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Valley TS, Nallamothu BK, Heung M, et al. Hospital Variation in Renal Replacement Therapy for Sepsis in the United States. Crit Care Med. 2018. PMID: 29206766. doi:10.1097/CCM.0000000000002878

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。